- Home
- IBRX vs NVG Comparison
IBRX vs NVG Comparison
Compare IBRX & NVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- NVG
- Stock Information
- Founded
- IBRX 2014
- NVG 1999
- Country
- IBRX United States
- NVG United States
- Employees
- IBRX N/A
- NVG N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- NVG Investment Managers
- Sector
- IBRX Health Care
- NVG Finance
- Exchange
- IBRX Nasdaq
- NVG Nasdaq
- Market Cap
- IBRX 2.4B
- NVG 2.7B
- IPO Year
- IBRX N/A
- NVG N/A
- Fundamental
- Price
- IBRX $4.49
- NVG $12.87
- Analyst Decision
- IBRX Buy
- NVG
- Analyst Count
- IBRX 2
- NVG 0
- Target Price
- IBRX $17.38
- NVG N/A
- AVG Volume (30 Days)
- IBRX 10.4M
- NVG 568.8K
- Earning Date
- IBRX 11-12-2024
- NVG 01-01-0001
- Dividend Yield
- IBRX N/A
- NVG 4.65%
- EPS Growth
- IBRX N/A
- NVG N/A
- EPS
- IBRX N/A
- NVG N/A
- Revenue
- IBRX $7,332,000.00
- NVG N/A
- Revenue This Year
- IBRX $1,563.18
- NVG N/A
- Revenue Next Year
- IBRX $1,262.20
- NVG N/A
- P/E Ratio
- IBRX N/A
- NVG N/A
- Revenue Growth
- IBRX 1218.71
- NVG N/A
- 52 Week Low
- IBRX $3.10
- NVG $9.68
- 52 Week High
- IBRX $10.53
- NVG $12.21
- Technical
- Relative Strength Index (RSI)
- IBRX 46.07
- NVG 49.07
- Support Level
- IBRX $4.57
- NVG $12.71
- Resistance Level
- IBRX $5.08
- NVG $13.08
- Average True Range (ATR)
- IBRX 0.54
- NVG 0.15
- MACD
- IBRX -0.12
- NVG 0.05
- Stochastic Oscillator
- IBRX 3.16
- NVG 68.84
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About NVG Nuveen AMT-Free Municipal Credit Income Fund
Nuveen AMT-Free Municipal Credit Income Fund is a diversified, closed-end management investment company. Its objective is to provide current income exempt from regular federal income tax. The Fund invests predominantly in investment grade municipal bonds that are exempt from regular federal income taxes.